Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 13, 2021 01:30 ET | Source: OSE Immunotherapeutics

Boehringer Ingelheim and OSE Immunotherapeutics to Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021

BI 765063, a first-in-class SIRPα inhibitor in the SIRPα/CD47 “Don’t eat me” pathway, is being developed under collaborative agreement between OSE Immunotherapeutics and Boehringer Ingelheim. ...
September 07, 2021 01:30 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Tedopi®

Further Strengthens Global Intellectual Property Portfolio for Tedopi®in Non-Small Cell Lung Cancer until 2035 NANTES, France, Sept. 07, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN:...
September 01, 2021 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

NANTES, France, Sept. 01, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173) today announced it will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The...
August 26, 2021 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer

Clinical trial sponsored and conducted by the French oncology cooperative group ARCAGY-GINECO and supported by Merck Sharp & Dohme Corp. (MSD), a subsidiary of Merck & Co., Inc., Kenilworth,...
August 25, 2021 12:00 ET | Source: OSE Immunotherapeutics

Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome

PARIS and NANTES, France, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group, and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE), a French biotech,...
August 24, 2021 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Upcoming Investor Conferences and R&D Day

NANTES, France, Aug. 24, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that the Company will be present at the following investor events: H.C....
July 19, 2021 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1 Study

NANTES, France, July 19, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announced a voluntary and temporary pause of enrollment and dosing in its ongoing...
July 09, 2021 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the First Tranche of the Financing Granted by the European Investment Bank

This financing will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in therapeutic areas with high unmet medical needs.This €10 million payment...
June 30, 2021 01:30 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Manufacturing Agreement with Cenexi for Clinical Batches of CoVepiT, OSE’s Multi-Target Second-Generation COVID-19 Vaccine

NANTES, France and FONTENAY-SOUS-BOIS, France, June 30, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) and Cenexi, a French contract development and manufacturing...
June 24, 2021 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Reports on its 2021 Virtual Combined General Shareholder’s Meeting

NANTES, France, June 24, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that all the resolutions submitted to a vote at the Combined General...